In early June 2019, some female colleagues went to Hong Kong to receive HPV9-valent vaccine. In line with the concept of caring for employees' physical and mental health, the Company has arranged for some female colleagues to go to Hong Kong to receive HPV9-valent vaccine since the end of 2018, and this is the last injection for this batch of colleagues.

The HPV 9-valent vaccine protects against 90% cervical cancers and is the world's most comprehensive and advanced version of the new combination vaccine that protects against cervical, vulvar, vaginal, and anal cancers, genital warts, persistent infections, precancerous lesions, or atypical lesions caused by these viruses. The vaccine is given in three doses, one at 0, 2 and 6 months.